Buscar
Trevi Therapeutics Inc
TRVIAñadir a la lista de seguimiento
17.535USD
+0.355+2.07%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
2.25BCap. mercado
PérdidaP/E TTM
Más Datos de Trevi Therapeutics Inc Compañía
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Información de Trevi Therapeutics Inc
Símbolo de cotizaciónTRVI
Nombre de la empresaTrevi Therapeutics Inc
Fecha de salida a bolsaMay 07, 2019
Director ejecutivoGood (Jennifer L)
Número de empleados26
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 07
Dirección195 Church Street
CiudadNEW HAVEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal06510
Teléfono12033042499
Sitio Webhttps://www.trevitherapeutics.com/
Símbolo de cotizaciónTRVI
Fecha de salida a bolsaMay 07, 2019
Director ejecutivoGood (Jennifer L)
Ejecutivos de Trevi Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
81.55K
+5.71%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
81.55K
+5.71%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Trevi Therapeutics Inc?
Los cinco principales accionistas de Trevi Therapeutics Inc son: Dr. David P. Meeker, M.D.
¿Cuántas instituciones poseen acciones de Trevi Therapeutics Inc (TRVI)?
A fecha de 2026Q1, 339 instituciones poseen acciones de Trevi Therapeutics Inc, con un valor de mercado combinado de aproximadamente 142.75M, lo que representa el 101.53% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5970560.00.